Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (292)	1/19/2007 4:48:50 PM
From: tuck	Read Replies (1) \| Respond to of 411

>>01-19-07 1619ET DJ CV Therapeutics Files $160M Common Stock Shelf >CVTX DOW JONES NEWSWIRES CV Therapeutics Inc. (CVTX) on Friday registered with the Securities and Exchange Commission to sell from time to time up to $160 million in common stock. The Palo Alto, Calif., biopharmaceutical company said it intends to use the net proceeds for general corporate purposes. No underwriters were listed in the filing. Shares of the company closed Friday at $14.45 each, up 55 cents, or almost 4%, from Thursday's close.<< A little Friday afternoon news nugget. Will they finance before or after MERLIN results are out? If the former, it would imply a lack of confidence. Cheers, Tuck